Afatinib Dimaleate CAS 850140-73-7 Kemurnian >99.5% (HPLC) API
Ruifu Chemical Supply Intermediates saka Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(Dimethylamino)acetaldehyde Diethyl Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7
Asam Dietilphosphonoacetic CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-siji CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineCAS 314771-88-5
Jeneng Kimia | Afatinib Dimaleate |
sinonim | BIBW2992 Dimaleate;(S,E)-N-(4-(3-Chloro-4-Fluorophenylamino)-7-(Tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)nanging-2-Enamide Dimaleate |
Nomer CAS | 618-89-3 |
Nomer CAT | RF-PI2032 |
Status Simpenan | Ing Simpenan, Skala Produksi Nganti Ton |
Formula Molekul | C32H33ClFN5O11 |
Bobot Molekul | 718.08 |
Sensitivitas | Kelembapan Sensitif |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Bubuk Putih nganti Putih |
Kemurnian / Metode Analisis | > 99,5% (HPLC) |
Mundhut ing Pangatusan | <0,50% |
Sisa ing Ignition | <0,10% |
Pengotor Tunggal Maksimum | <0,30% |
Total Impurities | <0,50% |
Logam Berat (Pb) | ≤20ppm |
Spektrum Infrared | Conforms kanggo Struktur |
NMR | Conforms kanggo Struktur |
Test Standar | Standar Perusahaan |
Urip beting | 24 Wulan yen disimpen kanthi bener |
Panggunaan | API |
Paket: Botol, tas Aluminium foil, 25kg / Karton Drum, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
Afatinib Dimaleate (CAS: 850140-73-7), wangun uyah dimaleate saka afanitib, minangka agen antineoplastik sing kasedhiya sacara lisan.Afatinib Dimaleate minangka inhibitor kulawarga EGFR sing ora bisa dibatalake kanthi IC50s 0,5 nM, 0,4 nM, 10 nM lan 14 nM kanggo EGFRwt, EGFRL858R, EGFRL858R / T790M lan HER2.Afatinib Dimaleate dituduhake kanggo perawatan lini pertama pasien kanker paru-paru sel non-small metastatik (NSCLC) sing tumor duwe penghapusan reseptor faktor pertumbuhan epidermal (EGFR) exon 19 utawa mutasi substitusi exon 21 (L858R) kaya sing dideteksi dening FDA- test disetujoni.Ing jaman biyen, perawatan standar kanthi regimen dobel kemoterapi adhedhasar platinum dianggep minangka terapi lini pertama standar kanggo kabeh pasien NSCLC.Nanging, bukti sing muncul wis nemtokake subpopulasi ing ngendi terapi sing ditargetake luwih efektif, nyebabake pangembangan obat khusus mutasi.Afatinib Dimaleate dikembangake dening Boehringer Ingelheim Pharmaceuticals, Afatinib Dimaleate disetujoni dening FDA ing 2013 minangka obat yatim piatu kanthi jeneng dagang Gilotrif.Afatinib Dimaleate disintesis kanthi kimia nggunakake metode standar.Afatinib Dimaleateora mung aktif nglawan mutasi EGFR sing ditargetake dening TKI generasi pertama kaya erlotinib utawa gefitinib, nanging uga nglawan mutasi kayata T790M sing ora sensitif marang terapi standar kasebut.Amarga aktivitas tambahan marang Her2, lagi diselidiki kanggo kanker payudara uga kanker EGFR lan Her2 liyane.